EB-2 NIWBiotech and pharmaEmployerDecided April 2025Sustained
Outcome: Sustained
APR302025_02B5203
Merit and national importanceMetWell positionedMetBalance favors a waiverMet
Our summary
A pharmaceutical researcher with advanced degree seeking EB-2 classification and national interest waiver for nanotechnology drug delivery research targeting cancer and HIV. AAO sustained appeal, finding all three Dhanasar prongs met: endeavor advances federal priorities, petitioner well-positioned through expertise and proven success, and waiver benefits U.S. public health.
Official PDF
Official PDF ↗Published by USCIS. The summary is ours, in our own words; the decision text is on uscis.gov.
What the AAO accepted
- Merit and national importance · Proposed research in nanotechnology drug delivery for cancer and HIV advances formally recognized critical federal priorities.
- Well positioned · Pharmaceutical researcher with considerable expertise, education, documented past successes in research and publishing track record.
- Balance favors a waiver · Track record of successful research and significance to public health interests provide contributions beneficial to United States.
What was missing
Every criterion in the table was found met.
Criteria
| Criterion | Reading | Why |
|---|---|---|
 Merit and national importance | Met | Proposed research in nanotechnology drug delivery for cancer and HIV advances formally recognized critical federal priorities. |
 Well positioned | Met | Pharmaceutical researcher with considerable expertise, education, documented past successes in research and publishing track record. |
 Balance favors a waiver | Met | Track record of successful research and significance to public health interests provide contributions beneficial to United States. |
A published decision describes one case. It is not legal advice and not a prediction for yours.